LL-37 – Comprehensive Research Overview (2026)

LL-37 is a 37-amino-acid cationic antimicrobial peptide (AMP) derived from the C-terminus of the human cathelicidin protein hCAP18. It is the only known human cathelicidin and serves as a critical component of innate immunity. LL-37 is researched for its antimicrobial, immunomodulatory, wound healing, and anti-biofilm properties. It is active against bacteria, viruses, and fungi, and also modulates inflammatory responses and promotes tissue repair.

→ View LL-37 (for laboratory research use only)

Mechanism of Action

  • Disrupts bacterial cell membranes via electrostatic interaction and pore formation (broad-spectrum antimicrobial).
  • Neutralizes LPS (endotoxin), reducing sepsis-related inflammation.
  • Modulates TLR signaling, balancing pro- and anti-inflammatory responses.
  • Promotes wound healing via keratinocyte migration, angiogenesis, and re-epithelialization.
  • Disrupts bacterial biofilms, including antibiotic-resistant strains.
  • Antiviral activity against influenza, HIV, and other enveloped viruses.

Clinical Evidence and Research Findings

LL-37 deficiency is associated with increased susceptibility to infections (e.g., atopic dermatitis, Kostmann syndrome). Clinical research explores topical LL-37 for chronic wounds, diabetic ulcers, and skin infections. Systemic research is growing for sepsis, respiratory infections, and inflammatory conditions. No large Phase 3 trials for systemic use, but topical applications have early human evidence.

→ Interested in researching LL-37? View Product Options

Benefits (Research & Clinical Observations)

  • Broad-spectrum antimicrobial activity (bacteria, viruses, fungi)
  • Anti-biofilm effects including antibiotic-resistant organisms
  • Wound healing and tissue repair promotion
  • Immunomodulation and endotoxin neutralization
  • Potential for sepsis and chronic infection research

Typical Dosing Protocols (Research)

  • Topical: Applied directly to wounds or skin infections in research settings
  • Subcutaneous (research): 1–5 mg per dose, frequency varies by protocol
  • Cycles: Acute use for infection/wound models; chronic use protocols vary

Safety Profile and Side Effects

LL-37 has a favorable safety profile at physiologic concentrations. At high concentrations, it can be cytotoxic to mammalian cells. Common side effects at research doses: mild injection-site reactions, transient inflammation. Dose-dependent cytotoxicity is the primary safety consideration.

Summary

LL-37 is the only human cathelicidin, serving as a critical innate immune effector with broad antimicrobial, immunomodulatory, and wound-healing properties. Its unique mechanism makes it a valuable research tool for infection, inflammation, and tissue repair. As with all compounds in this library, LL-37 is not an approved drug and should only be considered under qualified research supervision.

For Laboratory Research Use View LL-37 →

Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.